Compare WING & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WING | CRNX |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | 2015 | 2018 |
| Metric | WING | CRNX |
|---|---|---|
| Price | $116.82 | $84.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 27 | 8 |
| Target Price | ★ $295.92 | $76.75 |
| AVG Volume (30 Days) | 1.3M | ★ 3.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 67.84 | N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $696,853,000.00 | $1,039,000.00 |
| Revenue This Year | $17.20 | $720.10 |
| Revenue Next Year | $15.86 | $184.67 |
| P/E Ratio | $52.30 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $116.25 | $26.50 |
| 52 Week High | $345.81 | $84.09 |
| Indicator | WING | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 28.87 | 89.87 |
| Support Level | $116.35 | $43.40 |
| Resistance Level | $176.24 | $84.00 |
| Average True Range (ATR) | 8.67 | 0.21 |
| MACD | -1.79 | -1.71 |
| Stochastic Oscillator | 1.08 | 73.17 |
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.